keyword
MENU ▼
Read by QxMD icon Read
search

biomarkers hnscc

keyword
https://www.readbyqxmd.com/read/29431869/separation-of-plasma-derived-exosomes-into-cd3-and-cd3-fractions-allows-for-association-of-immune-cell-and-tumor-cell-markers-with-disease-activity-in-hnscc-patients
#1
Marie-Nicole Theodoraki, Thomas K Hoffmann, Theresa L Whiteside
Head and neck squamous cell carcinoma (HNSCC) is a highly immunosuppressive malignancy. Exosomes in HNSCC patients' plasma are enriched in inhibitory cargo and mediate immunosuppression. As these exosomes are products of various cells, the cellular origin of immunoregulatory proteins they carry is unknown. To test whether tumor- or T cell-derived exosomes in patient's plasma are immunosuppressive and impact on disease activity, we separated CD3(-) from CD3(+) exosomes by immunocapture using anti-CD3 Abs. The exosome protein cargo was evaluated for immunoregulatory proteins using on-bead flow cytometry...
February 12, 2018: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/29428866/prognostic-value-of-circulating-biomarker-score-in-advanced-stage-head-and-neck-squamous-cell-carcinoma
#2
Marn Joon Park, Jong-Lyel Roh, Sung-Bae Kim, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim
BACKGROUND: Circulating biomarker (CB) is a convenient, emerging predictive tool for treatment response and outcomes in human cancers. Therefore, we examined the prognostic value of pre-treatment and early post-treatment CBs and their summated scores in patients with head and neck squamous cell carcinoma (HNSCC). METHODS: This study prospectively included 310 consecutive patients who underwent definitive treatment for previously untreated advanced-stage HNSCC between 2010 and 2015...
February 8, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29425237/intragenic-dna-methylation-of-pitx1-and-the-adjacent-long-non-coding-rna-c5orf66-as1-are-prognostic-biomarkers-in-patients-with-head-and-neck-squamous-cell-carcinomas
#3
Verena Sailer, Arthur Charpentier, Joern Dietrich, Timo J Vogt, Alina Franzen, Friedrich Bootz, Dimo Dietrich, Andreas Schroeck
BACKGROUND: Patients with squamous cell cancer of the head and neck region (HNSCC) are at risk for disease recurrence and metastases, even after initial successful therapy. A tissue-based biomarker could be beneficial to guide treatment as well as post-treatment surveillance. Gene methylation status has been recently identified as powerful prognostic biomarker in HNSCC. We therefore evaluated the methylation status of the homeobox gene PITX1 and the adjacent long intergenic non-coding RNA (lincRNA) C5orf66-AS1 in publicly available datasets...
2018: PloS One
https://www.readbyqxmd.com/read/29423108/cancer-immunogenomic-approach-to-neoantigen-discovery-in-a-checkpoint-blockade-responsive-murine-model-of-oral-cavity-squamous-cell-carcinoma
#4
Paul Zolkind, Dariusz Przybylski, Nemanja Marjanovic, Lan Nguyen, Tianxiang Lin, Tanner Johanns, Anton Alexandrov, Liye Zhou, Clint T Allen, Alexander P Miceli, Robert D Schreiber, Maxim Artyomov, Gavin P Dunn, Ravindra Uppaluri
Head and neck squamous cell carcinomas (HNSCC) are an ideal immunotherapy target due to their high mutation burden and frequent infiltration with lymphocytes. Preclinical models to investigate targeted and combination therapies as well as defining biomarkers to guide treatment represent an important need in the field. Immunogenomics approaches have illuminated the role of mutation-derived tumor neoantigens as potential biomarkers of response to checkpoint blockade as well as representing therapeutic vaccines...
January 9, 2018: Oncotarget
https://www.readbyqxmd.com/read/29420101/leveraging-genomics-for-head-and-neck-cancer-treatment
#5
J D Kemmer, D E Johnson, J R Grandis
The genomic landscape of head and neck squamous cell carcinoma (HNSCC) has been recently elucidated. Key epigenetic and genetic characteristics of this cancer have been reported and substantiated in multiple data sets, including those distinctive to the growing subset of human papilloma virus (HPV)-associated tumors. This increased understanding of the molecular underpinnings of HNSCC has not resulted in new approaches to treatment. Three Food and Drug Administration-approved molecular targeting agents are currently available to treat recurrent/metastatic disease, but these have exhibited efficacy only in subsets of HNSCC patients, and thus surgery, chemotherapy, and/or radiation remain as standard approaches...
February 1, 2018: Journal of Dental Research
https://www.readbyqxmd.com/read/29416641/-pd-l1-cd274-and-pd-l2-pdcd1lg2-promoter-methylation-is-associated-with-hpv-infection-and-transcriptional-repression-in-head-and-neck-squamous-cell-carcinomas
#6
Alina Franzen, Timo J Vogt, Tim Müller, Jörn Dietrich, Andreas Schröck, Carsten Golletz, Peter Brossart, Friedrich Bootz, Jennifer Landsberg, Glen Kristiansen, Dimo Dietrich
Background: DNA methylation of the immune checkpoint gene PD-L1 has recently been shown to be associated with PD-L1 mRNA expression in various malignancies. This study aimed to investigate the association of PD-L1 and PD-L2 methylation with mRNA expression, immune cell infitration, protein expression and human papilloma virus (HPV) infection in head and neck squamous cell carcinoma (HNSCC) patients. Results: DNA methylation of PD-L1 and PD-L2 correlates inversely with mRNA expression ( PD-L1 : p ≤ 0...
January 2, 2018: Oncotarget
https://www.readbyqxmd.com/read/29399358/predictive-biomarkers-for-combined-chemotherapy-with-5-fluorouracil-and-cisplatin-in-oro-and-hypopharyngeal-cancers
#7
Yasuhisa Hasegawa, Mitsuo Goto, Nobuhiro Hanai, Taijiro Ozawa, Hitoshi Hirakawa
The present study aimed to identify significant correlations between gene expression and chemotherapy response to 5-fluorouracil (5-FU)/cisplatin in head and neck squamous cell carcinoma (HNSCC), and to identify patients who would benefit from induction chemotherapy for both organ preservation and survival. A total of 64 patients who underwent radical treatment for HNSCC were enrolled. All patients received induction chemotherapy with 5-FU/cisplatin and tumor responses were evaluated. Pretreatment biopsy specimens from all patients were assayed for mRNA expression of thymidylate synthase, dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase, tymidine phosphorylase, glutathione S-transferase-pi, p53, RB Transcriptional Corepressor 1, B-cell lymphoma 2 (Bcl-2), Bcl-xL, E2F Transcription Factor 1, epidermal growth factor receptor, human epidermal growth factor receptor 2, phosphoinositide 3-kinase, phosphatase and tensin homolog, vascular endothelial growth factor (VEGF), cyclooxygenase-2, XPA, DNA Damage Recognition And Repair Factor, excision repair cross-complementing 1 (ERCC1), multidrug resistance gene 1 (MDR1), multidrug resistance-associated protein 1, equilibrative nucleoside transporter 1 and β-tubulin by reverse transcription-quantitative polymerase chain reaction, and the association between the expression levels of these genes and patient response to chemotherapy was determined...
February 2018: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29384959/pembrolizumab-for-recurrent-metastatic-head-and-neck-squamous-cell-carcinoma-in-an-asian-population
#8
Wen-Chun Chen, Pen-Yuan Chu, Yu-Ting Lee, Wen-Bin Lu, Chun-Yu Liu, Peter Mu-Hsin Chang, Muh-Hwa Yang
Head and neck squamous cell carcinoma (HNSCC) has a high prevalence and is a major cause of cancer deaths in Taiwan. However, there is still no effective salvage therapy that prolongs the life expectancy of patients with recurrent/metastatic (R/M) HNSCC. Immune checkpoint therapy that targets the programmed cell death protein 1 (PD-1) may provide clinical benefit for these patients. We analyzed 22 R/M HNSCC patients who received pembrolizumab, a monoclonal antibody against PD-1, as salvage therapy. Intravenous pembrolizumab was given at a fixed dosage of 100 or 200 mg every 3 weeks...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29374693/association-of-eif4e-and-sparc-expression-with-lymphangiogenesis-and-lymph-node-metastasis-in-hypopharyngeal-cancer
#9
Benjamin Philipp Ernst, Caja Mikstas, Timo Stöver, Roland Stauber, Sebastian Strieth
BACKGROUND/AIM: Head and neck squamous cell carcinomas (HNSCC) are characterized by aggressiveness, early recurrence and lymph node metastasis. Therefore, there is an urgent need to identify new biomarkers and drug targets. MATERIALS AND METHODS: Neck dissection specimens from 11 patients diagnosed with hypopharyngeal cancer were analyzed for their lymphatic vessel density (LVD) by lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) immunostaining, expression of eukaryotic initiation factor 4E (eIF4E) and levels of secreted protein acidic and rich in cysteine (SPARC) using immunoblot analysis...
February 2018: Anticancer Research
https://www.readbyqxmd.com/read/29355614/head-and-neck-squamous-cell-carcinoma-genomics-and-emerging-biomarkers-for-immunomodulatory-cancer-treatments
#10
REVIEW
Benjamin Solomon, Richard J Young, Danny Rischin
Head and neck squamous cell carcinoma (HNSCC) comprises a heterogeneous group of tumors that arise from the squamous epithelium of the oral cavity, oropharynx, larynx and hypopharynx. While many HNSCCs are related to classical etiologic factors of smoking and alcohol, a clinically, genomically, and immunologically distinct subgroup of tumors arise from the epithelium of the tonsil and the base of tongue as a result of infection with Human Papilloma Virus (HPV). In this review we describe the genomic and immunologic landscape of HNSCC, highlighting differences between HPV-positive and HPV-negative HNSCC...
January 17, 2018: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/29331751/comprehensive-genomic-profiling-of-head-and-neck-squamous-cell-carcinoma-reveals-fgfr1-amplifications-and-tumour-genomic-alterations-burden-as-prognostic-biomarkers-of-survival
#11
C Dubot, V Bernard, M P Sablin, S Vacher, W Chemlali, A Schnitzler, G Pierron, K Ait Rais, N Bessoltane, E Jeannot, J Klijanienko, O Mariani, T Jouffroy, V Calugaru, C Hoffmann, M Lesnik, N Badois, F Berger, C Le Tourneau, M Kamal, I Bieche
BACKGROUND: We aimed at identifying deleterious genomic alterations from untreated head and neck squamous cell carcinoma (HNSCC) patients, and assessing their prognostic value. PATIENTS AND METHODS: We retrieved 122 HNSCC patients who underwent primary surgery. Targeted NGS was used to analyse a panel of 100 genes selected among the most frequently altered genes in HNSCC and potential therapeutic targets. We selected only deleterious (activating or inactivating) single nucleotide variations, and copy number variations for analysis...
January 10, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29306329/gene-expression-signature-regulated-by-the-keap1-nrf2-cul3-axis-is-associated-with-a-poor-prognosis-in-head-and-neck-squamous-cell-cancer
#12
Akhileshwar Namani, Md Matiur Rahaman, Ming Chen, Xiuwen Tang
BACKGROUND: NRF2 is the key regulator of oxidative stress in normal cells and aberrant expression of the NRF2 pathway due to genetic alterations in the KEAP1 (Kelch-like ECH-associated protein 1)-NRF2 (nuclear factor erythroid 2 like 2)-CUL3 (cullin 3) axis leads to tumorigenesis and drug resistance in many cancers including head and neck squamous cell cancer (HNSCC). The main goal of this study was to identify specific genes regulated by the KEAP1-NRF2-CUL3 axis in HNSCC patients, to assess the prognostic value of this gene signature in different cohorts, and to reveal potential biomarkers...
January 6, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29289845/decreased-plasma-dek-oncogene-levels-correlate-with-p16-negative-disease-and-advanced-tumor-stage-in-a-case-control-study-of-patients-with-head-and-neck-squamous-cell-carcinoma
#13
Trisha Wise-Draper, Arun Sendilnathan, Sarah Palackdharry, Nicholas Pease, Julianne Qualtieri, Randall Butler, Nooshin Hashemi Sadraei, John C Morris, Yash Patil, Keith Wilson, Jonathan Mark, Keith Casper, Vinita Takiar, Adam Lane, Lisa Privette Vinnedge
Head and neck cancer (HNC) remains the sixth most common malignancy worldwide and survival upon recurrence and/or metastasis remains poor. HNSCC has traditionally been associated with alcohol and nicotine use, but more recently the Human Papilloma Virus (HPV) has emerged as a favorable prognostic risk factor for oropharyngeal HNSCC. However, further stratification with additional biomarkers to predict patient outcome continues to be essential. One candidate biomarker is the DEK oncogenic protein, which was previously detected in the urine of patients with bladder cancer and is known to be secreted by immune cells such as macrophages...
December 28, 2017: Translational Oncology
https://www.readbyqxmd.com/read/29282038/the-prognostic-value-of-tp53-mutations-in-hypopharyngeal-squamous-cell-carcinoma
#14
Go Omura, Mizuo Ando, Yasuhiro Ebihara, Yuki Saito, Kenya Kobayashi, Osamu Fukuoka, Ken Akashi, Masafumi Yoshida, Takahiro Asakage, Tatsuya Yamasoba
BACKGROUND: TP53 is the most frequently mutated gene in human cancers. Previous studies reported that TP53 mutations correlated with poor prognoses in patients with head and neck squamous cell carcinoma (HNSCC). However, the relationship between TP53 mutations and hypopharyngeal squamous cell carcinoma (HPSCC) is not known. The current study aimed to evaluate TP53 mutation status as a predictive biomarker in patients with HPSCC. METHODS: We retrospectively reviewed the clinical charts of 57 HPSCC patients treated with initial surgery between 2008 and 2014...
December 28, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29259267/dysregulation-of-mir-196b-in-head-and-neck-cancers-leads-to-pleiotropic-effects-in-the-tumor-cells-and-surrounding-stromal-fibroblasts
#15
Saúl Álvarez-Teijeiro, Sofía T Menéndez, M Ángeles Villaronga, Juan P Rodrigo, Lorea Manterola, Lucas de Villalaín, Juan C de Vicente, Laura Alonso-Durán, M Pilar Fernández, Charles H Lawrie, Juana M García-Pedrero
The miR-196 family members have been found dysregulated in different cancers. Therefore, they have been proposed as promising biomarkers and therapeutic targets. This study is the first to investigate the role of miR-196b in the development and progression of head and neck squamous cell carcinomas (HNSCC), and also the impact on the surrounding tumor microenvironment. Increased miR-196b levels were detected in 95% of primary tumors and precancerous lesions, although no significant differences were observed between non-progressing versus progressing dysplasias...
December 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29245977/the-cancer-testis-antigen-sperm-protein-17-a-new-biomarker-and-immunological-target-in-head-and-neck-squamous-cell-carcinoma
#16
Christopher A Schutt, Leonardo Mirandola, Jose A Figueroa, Diane D Nguyen, Joehassin Cordero, Klauss Bumm, Benjamin L Judson, Maurizio Chiriva-Internati
Head and Neck Squamous Cell Carcinoma is a deadly and locally aggressive malignancy that frequently portends a poor prognosis. Since current treatment modalities including surgery, chemotherapy and radiation are heavily debilitating and often result in recurrence intense efforts have been put into the development of novel less toxic and more lasting treatment strategies. Recently, immunotherapy has been proposed as a promising alternative that could potentially meet these requirements. SP17 is a validated cancer-testis antigen in multiple myeloma, ovarian cancer and non-small cell lung cancer...
November 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/29229598/cdkn2a-p16-deletion-in-head-and-neck-cancer-cells-is-associated-with-cdk2-activation-replication-stress-and-vulnerability-to-chk1-inhibition
#17
Mayur A Gadhikar, Jiexin Zhang, Li Shen, Xiayu Rao, Jing Wang, Mei Zhao, Nene N Kalu, Faye M Johnson, Lauren A Byers, John Heymach, Walter N Hittelman, Durga Udayakumar, Raj K Pandita, Tej K Pandita, Curtis R Pickering, Abena Redwood, Helen Piwnica-Worms, Katharina Schlacher, Mitchell J Frederick, Jeffrey N Myers
Checkpoint kinase inhibitors (CHKi) exhibit striking single agent activity in certain tumors, but the mechanisms accounting for hypersensitivity are poorly understood. We screened a panel of 49 established human head and neck squamous cell carcinoma (HNSCC) cell lines and report that nearly 20% are hypersensitive to CHKi monotherapy. Hypersensitive cells underwent early S-phase arrest at drug doses sufficient to inhibit greater than 90% of Chk1 activity. Reduced rate of DNA replication fork progression and chromosomal shattering were also observed, suggesting replication stress as a root causative factor in CHKi hypersensitivity...
December 11, 2017: Cancer Research
https://www.readbyqxmd.com/read/29224828/cell-free-nucleic-acids-in-body-fluids-as-biomarkers-for-the-prediction-and-early-detection-of-recurrent-head-and-neck-cancer-a-systematic-review-of-the-literature
#18
REVIEW
Joost H van Ginkel, Fons J B Slieker, Remco de Bree, Robert J J van Es, Ellen M Van Cann, Stefan M Willems
Liquid biopsy is a minimally invasive detection method for molecular biomarkers in body fluids which may serve as a novel tool in management of head and neck cancer. The purpose of this systematic review is to outline the current status of liquid biopsy in head and neck squamous cell carcinoma (HNSCC) patients by systematically identifying and qualifying all published studies on the diagnostic or prognostic value of cell-free nucleic acids detection for posttreatment disease monitoring and/or disease outcome...
December 2017: Oral Oncology
https://www.readbyqxmd.com/read/29224824/circulating-tumour-cell-pd-l1-test-for-head-and-neck-cancers
#19
Arutha Kulasinghe, Liz Kenny, Chamindie Punyadeera
Immune checkpoint inhibitors have gained traction over the last few years in the treatment of metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) patients. Monoclonal antibodies that block the programmed death 1 (PD-1) receptor and its major ligand, PD-L1, have shown durable responses and low toxicity profiles. There are currently no validated predictive biomarkers to select patients likely to respond to anti-PD-1/PD-L1 therapy to avoid unwanted side effects and to reduce healthcare expenditure...
December 2017: Oral Oncology
https://www.readbyqxmd.com/read/29213339/comparison-of-quantification-algorithms-for-circulating-cell-free-dna-methylation-biomarkers-in-blood-plasma-from-cancer-patients
#20
Luka de Vos, Heidrun Gevensleben, Andreas Schröck, Alina Franzen, Glen Kristiansen, Friedrich Bootz, Dimo Dietrich
Background: SHOX2 and SEPT9 methylation in circulating cell-free DNA (ccfDNA) in blood are established powerful and clinically valuable biomarkers for diagnosis, staging, prognosis, and monitoring of cancer patients. The aim of the present study was to evaluate different quantification algorithms (relative quantification, absolute quantification, quasi-digital PCR) with regard to their clinical performance. Methods: Methylation analyses were performed in a training cohort (141 patients with head and neck squamous cell carcinoma [HNSCC], 170 control cases) and a testing cohort (137 HNSCC cases, 102 controls)...
2017: Clinical Epigenetics
keyword
keyword
54951
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"